Trametinib: A Targeted Therapy in Metastatic Melanoma
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Katherine Benchich, MSN, NP-C, AOCNP®
University of Colorado Cancer Center, Aurora, Colorado
Authors’ disclosures of conflicts of interest are found at the end of this article.
Brianna Hoffner, MSN, ANP-BC, AOCNP®, 1665 Aurora Court, 2nd floor, Aurora, CO 80045. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2018;9(7):741–745 |
© 2018 Harborside™
Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. It is a once-daily oral medication that was approved based on progression-free survival and overall survival advantage compared to chemotherapy. Most common side effects include rash, diarrhea, peripheral edema, and fatigue. When used in combination with dabrafenib, pyrexia and nausea are also common. Most side effects can be managed effectively with dose interruptions, supportive care, and/or dose reductions. Ongoing trials are investigating the use of targeted therapy in combination with immunotherapy for cutaneous melanoma and other malignancies. The treatment landscape for metastatic melanoma continues to evolve. However, targeted therapy with trametinib remains a fast-acting and efficacious option, particularly when used in combination with dabrafenib.
For access to the full length article, please sign in